In part 4 of our interview, we learn more about nipocalimab’s safety profile and how this investigative agent might address ...

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent ...